EVX-01's three-year melanoma data will test whether durable neoantigen vaccine responses translate to survival benefit that can attract a partner or support advancement

Bull

A positive outcome would show deepened or maintained objective responses beyond the 75% ORR and 92% durability seen at two years, with monotherapy dosing in year three demonstrating vaccine-intrinsic efficacy independent of prior combination partners. Such data would provide compelling evidence that AI-designed neoantigen vaccines can drive durable tumor control, materially strengthening the case for a partnership or licensing deal analogous to the EVX-B3 transaction with MSD.

Bear

The most likely failure modes are response attrition over year three — where the 92% two-year durability figure erodes significantly — or failure of monotherapy dosing to sustain tumor control without combination support, suggesting the vaccine alone is insufficient. With only 16 patients in the Phase 2, the dataset remains small and any signal of progression in even a few patients could undermine confidence in the survival benefit narrative that underpins the thesis.